Does Anybody Want an Injectable Rotavirus Vaccine, and Why? Understanding the Public Health Value Proposition of Next-Generation Rotavirus Vaccines
Open Access
Abstract
Routine infant immunization with live, oral rotavirus vaccines (LORVs) has had a major impact on severe gastroenteritis disease. Nevertheless, in high morbidity and mortality settings rotavirus remains an important cause of disease, partly attributable to the sub-optimal clinical efficacy of LORVs in those settings. Regardless of the precise immunological mechanism(s) underlying the diminished efficacy, the introduction of injectable next-generation rotavirus vaccines (iNGRV), currently in clinical development, could offer a potent remedy. In addition to the potential for greater clinical efficacy, precisely how iNGRVs are delivered (multiple doses to young infants; alongside LORVs or as a booster; co-formulated with Diphtheria-Tetanus-Pertussis (DTP)-containing vaccines), their pricing, and their storage and cold chain characteristics could each have major implications on the resultant health outcomes, on cost-effectiveness as well as on product preferences by national stakeholders and healthcare providers. To better understand these implications, we critically assessed whether there is a compelling public health value proposition for iNGRVs based on potential (but still hypothetical) vaccine profiles. Our results suggest that the answer is highly dependent on the specific use cases and potential attributes of such novel vaccines. Notably, co-formulation of iNGRVs with similar or greater efficacy than LORVs with a DTP-containing vaccine, such as DTP-Hib-HepB, scored especially high on potential impact, cost-effectiveness, and strength of preference by national stakeholders and health care providers in lower and middle income countries.Keywords
Funding Information
- Bill and Melinda Gates Foundation (OPP 1203883)
This publication has 30 references indexed in Scilit:
- Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016The Lancet Infectious Diseases, 2018
- Human Neonatal Rotavirus Vaccine (RV3-BB) to Target Rotavirus from BirthNew England Journal of Medicine, 2018
- Waxing Understanding of Waning ImmunityThe Journal of Infectious Diseases, 2018
- Quantifying the Impact of Natural Immunity on Rotavirus Vaccine Efficacy Estimates: A Clinical Trial in Dhaka, Bangladesh (PROVIDE) and a Simulation StudyThe Journal of Infectious Diseases, 2018
- Potential for a booster dose of rotavirus vaccine to further reduce diarrhea mortalityVaccine, 2017
- Estimating the full public health value of vaccinationVaccine, 2017
- Estimating global, regional and national rotavirus deaths in children aged <5 years: Current approaches, new analyses and proposed improvementsPLOS ONE, 2017
- Effectiveness of Rotavirus Vaccination: A Systematic Review of the First Decade of Global Postlicensure Data, 2006–2016Clinical Infectious Diseases, 2017
- Prime-boost vaccine strategy against viral infections: Mechanisms and benefitsVaccine, 2016
- Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control studyThe Lancet, 2013